⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

July 9, 2024Lung CancerOpen Access

Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in Extensive-Stage small cell lung cancer (ES-SCLC) patients: A large French multicenter study

Elvire Pons‐Tostivint Rémy Ezzedine Thomas Goronflot Perrine Créquit Thierry Chatellier Judith Raimbourg Jaafar Bennouna Etienne Giroux‐Leprieur Marie Porte

View Full Paper

Ask AI

Bookmark

Share

Abstract

Chemotherapy combined with immunotherapy (CT-IO) is the standard treatment for patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC). This study evaluates the effectiveness of second-line (2L) following CT-IO.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Pons‐Tostivint et al. (2024) studied this question.

synapsesocial.com/papers/68e60e3db6db6435875a0e55 https://doi.org/10.1016/j.lungcan.2024.107887

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Second-line treatment outcomes following first-line chemotherapy plus immunotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC): A multicenter study.2024 · 1 citations
2202P Clinical outcomes to second-line treatment, after failing chemoimmunotherapy, in ES-SCLC2024 · 1 citations
3Abstract 5098: Second-line treatment outcomes in Extensive Stage Small Cell Lung Cancer (ES-SCLC) patients after first-line immuno-chemotherapy2024
4Immunotherapy in Extensive Stage Small-Cell Lung Cancer in First-Line and Second-Line Setting2025
5203P Treatment patterns and real-world outcomes of extensive-stage small cell lung cancer: A retrospective, multicenter study2024 · 2 citations